CN103638450A - Preparation method and application of banksia rose qi-rectifying tablet - Google Patents
Preparation method and application of banksia rose qi-rectifying tablet Download PDFInfo
- Publication number
- CN103638450A CN103638450A CN201310593572.0A CN201310593572A CN103638450A CN 103638450 A CN103638450 A CN 103638450A CN 201310593572 A CN201310593572 A CN 201310593572A CN 103638450 A CN103638450 A CN 103638450A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tablet
- muxiangliqi
- radix
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method and application of a banksia rose qi-rectifying tablet. The banksia rose qi-rectifying tablet is prepared by supercritical extraction and microwave extraction of raw material medicines comprising 280 g of astragalus, 80 g of michelia hedyosperma lew, 190 g of angelica, 220 g of eclipta, 190 g of rhizoma atractylodis, 150 g of safflower, 140 g of radix paeoniae rubra, 140 g of peach kernel, 150 g of radix achyranthis bidentatae, 120 g of rhizoma ligustici wallichii, 70 g of bitter orange and 100 g of platycodon, and the content of baicalin is greatly improved. The present invention also provides the application of the banksia rose qi-rectifying tablet in preparation of drugs for inhibiting cell proliferation of mice breast cancer cell C127.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of preparation method and application of Muxiangliqi Tablet.
Background technology
Muxiangliqi Tablet standard No. WS-11113(ZD-1113)-2002, be recorded in national standard for traditional Chinese medicines compilation internal medicine taste fascicle.By Radix Aucklandiae 48g, Rhizoma Cyperi (processed with vinegar) 96g, Radix Linderae 96g, Pericarpium Citri Reticulatae Viride (processed with vinegar) 48g, Pericarpium Citri Reticulatae 96g, Fructus Aurantii Immaturus 96g, Fructus Aurantii 96g, stir-frying with ginger juice Cortex Magnoliae Officinalis 96g, vinegar Rhizoma Sparganii 24g processed, vinegar boil Rhizoma Curcumae 24g, Fructus Crataegi 96g, Semen Arecae 120g, Fructus Evodiae (processed) 12g, Cortex Cinnamomi 12g, Radix Et Rhizoma Nardostachyos 15g, Radix Platycodonis 48g, Radix Scutellariae 96g, Radix Et Rhizoma Rhei 48g, Semen Pharbitidis (parched) 48g make as crude drug, there is promoting the circulation of QI to alleviate the stagnation in middle-JIAO, change the effect of stagnant relieving constipation.For depression of QI, to stop eating and cut off the water, breast side of body painful abdominal mass is vexed, distension and fullness in the abdomen, nausea and vomiting, falls to satisfy noisy, constipation.
In prior art, not yet there is Muxiangliqi Tablet aspect extraction preparation, adopting the report of supercritical and microwave technology, and Chinese medicine is directly beaten powder, volatile oil extracts, the method that decocting boils, technique is coarse, backward, and impurity is many, causes patient's consumption excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
In order to solve above-mentioned technical problem, the invention provides a kind of preparation method of Muxiangliqi Tablet.
Another object of the present invention is to provide a kind of Muxiangliqi Tablet to suppress the application in mouse mammary tumor cell C127 cell proliferation medicine in preparation.
The object of the invention is to realize by following scheme:
A kind of preparation method of Muxiangliqi Tablet, by Radix Aucklandiae 48g, Rhizoma Cyperi (processed with vinegar) 96g, Radix Linderae 96g, Pericarpium Citri Reticulatae Viride (processed with vinegar) 48g, Pericarpium Citri Reticulatae 96g, Fructus Aurantii Immaturus 96g, Fructus Aurantii 96g, stir-frying with ginger juice Cortex Magnoliae Officinalis 96g, vinegar Rhizoma Sparganii 24g processed, vinegar boils Rhizoma Curcumae 24g, Fructus Crataegi 96g, Semen Arecae 120g, Fructus Evodiae (processed) 12g, Cortex Cinnamomi 12g, Radix Et Rhizoma Nardostachyos 15g, Radix Platycodonis 48g, Radix Scutellariae 96g, Radix Et Rhizoma Rhei 48g, Semen Pharbitidis (parched) 48g makes as crude drug, described preparation method is comprised of the following step: get the Radix Aucklandiae, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Fructus Aurantii Immaturus, Fructus Aurantii, Radix Et Rhizoma Nardostachyos, join in CO2 supercritical extraction device, ethanol is as entrainer, the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO2 flow l-3ml/g crude drug min, extraction time 180-220min, obtain supercritical extract, standby, get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extracts 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby, above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 500, every heavy 0.5g.
In the preparation method of above-mentioned Muxiangliqi Tablet, described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
In the preparation method of above-mentioned Muxiangliqi Tablet, described CO
2in supercritical extraction, extracting pressure is 25 MPa.
In the preparation method of above-mentioned Muxiangliqi Tablet, described CO
2in supercritical extraction, extraction temperature is 60 ℃.
In the preparation method of above-mentioned Muxiangliqi Tablet, described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
In the preparation method of above-mentioned Muxiangliqi Tablet, described CO
2in supercritical extraction, extraction time is 200min.
In the preparation method of above-mentioned Muxiangliqi Tablet, described microwave extracting power is 700W.
In the preparation method of above-mentioned Muxiangliqi Tablet, the each extraction time of described microwave extracting is 8 minutes.
Above-mentioned Muxiangliqi Tablet suppresses the application in mouse mammary tumor cell C127 cell proliferation medicine in preparation.
In prior art, Muxiangliqi Tablet is oral, one time 4～8,2 times on the one.Muxiangliqi Tablet dosage is large.The every heavy 0.5g of Muxiangliqi Tablet that adopts the inventive method to be prepared into only needs 2-4 sheet at every turn, within 1st, takes 2 times.Greatly reduced dose having under the condition of more active component.This conclusion can be by following evidence.
The comparison of content of baicalin in Muxiangliqi Tablet prepared by test one, distinct methods
L, instrument and reagent Muxiangliqi Tablet of the present invention: press embodiment 1 method preparation, use 1215g crude drug, make 500 through extracting, every heavy 0.5g.Former Muxiangliqi Tablet, according to WS-11113(ZD-1113)-2002 standard method preparations, in contrast.Agilent1200 high performance liquid chromatograph; METTLER AE240 electronic analytical balance; Baicalin reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
According to high performance liquid chromatography (appendix V D of Chinese Pharmacopoeia version in 2010), measure.
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Methanol-water-glacial acetic acid (35: 61: 4) is mobile phase; Detection wavelength is 283nm.Number of theoretical plate is pressed the calculating of baicalin peak should be lower than 2500.
The preparation precision of reference substance solution takes at 60 ℃ of drying under reduced pressure baicalin reference substance of 4 hours appropriate, adds methanol and makes every 1ml containing the solution of 0.04mg, obtains.
Muxiangliqi Tablet of the present invention is got in the preparation of product need testing solution of the present invention, and porphyrize is got 1g, accurately weighed, puts in 100ml measuring bottle, add water 30ml, put in water-bath and heat 30 minutes, add methanol 50ml, supersound process 30 minutes, lets cool, add methanol to scale, shake up, filter, get subsequent filtrate, obtain.
The Muxiangliqi Tablet of contrast is got in the preparation of reference product need testing solution, and porphyrize is got 1g, accurately weighed, puts in 100ml measuring bottle, add water 30ml, put in water-bath and heat 30 minutes, add methanol 50ml, supersound process 30 minutes, lets cool, add methanol to scale, shake up, filter, get subsequent filtrate, obtain.
Algoscopy is accurate reference substance solution and each 10 L of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
3, result
Result shows, in Muxiangliqi Tablet of the present invention, the content of baicalin is 4-7mg/ sheet; And the content of baicalin is 0.9mg/ sheet in former Muxiangliqi Tablet, doubly, in the situation that dose reduces, content of baicalin improves a lot the 4-8 that every content of baicalin is equivalent to former tablet content.
Above-mentioned research shows, the Muxiangliqi Tablet that adopts preparation method of the present invention to prepare, active constituent content is far away higher than WS-11113(ZD-1113) Muxiangliqi Tablet prepared of the method recorded of-2002 standards.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get Radix Aucklandiae 48g, Rhizoma Cyperi (processed with vinegar) 96g, Radix Linderae 96g, Pericarpium Citri Reticulatae Viride (processed with vinegar) 48g, Pericarpium Citri Reticulatae 96g, Fructus Aurantii Immaturus 96g, Fructus Aurantii 96g, stir-frying with ginger juice Cortex Magnoliae Officinalis 96g, vinegar Rhizoma Sparganii 24g processed, vinegar boils Rhizoma Curcumae 24g, Fructus Crataegi 96g, Semen Arecae 120g, Fructus Evodiae (processed) 12g, Cortex Cinnamomi 12g, Radix Et Rhizoma Nardostachyos 15g, Radix Platycodonis 48g, Radix Scutellariae 96g, Radix Et Rhizoma Rhei 48g, Semen Pharbitidis (parched) 48g, and the Radix Aucklandiae, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Fructus Aurantii Immaturus, Fructus Aurantii, Radix Et Rhizoma Nardostachyos are joined to CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, 40 ℃ of temperature, CO
2flow 2ml/g crude drug min, extraction time 200min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 700W, extracts 2 times, each 8 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 500, every heavy 0.5g.
After testing, in finished product, the content of baicalin is 6.22mg/ sheet.
Embodiment 2
Get Radix Aucklandiae 48g, Rhizoma Cyperi (processed with vinegar) 96g, Radix Linderae 96g, Pericarpium Citri Reticulatae Viride (processed with vinegar) 48g, Pericarpium Citri Reticulatae 96g, Fructus Aurantii Immaturus 96g, Fructus Aurantii 96g, stir-frying with ginger juice Cortex Magnoliae Officinalis 96g, vinegar Rhizoma Sparganii 24g processed, vinegar boils Rhizoma Curcumae 24g, Fructus Crataegi 96g, Semen Arecae 120g, Fructus Evodiae (processed) 12g, Cortex Cinnamomi 12g, Radix Et Rhizoma Nardostachyos 15g, Radix Platycodonis 48g, Radix Scutellariae 96g, Radix Et Rhizoma Rhei 48g, Semen Pharbitidis (parched) 48g, and the Radix Aucklandiae, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Fructus Aurantii Immaturus, Fructus Aurantii, Radix Et Rhizoma Nardostachyos are joined to CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 30MPa, temperature 50 C, CO
2flow 3ml/g crude drug min, extraction time 180min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600W, extracts 2 times, each 5 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 500, every heavy 0.5g.
After testing, in finished product, the content of baicalin is 5.78mg/ sheet.
Embodiment 3
Get Radix Aucklandiae 48g, Rhizoma Cyperi (processed with vinegar) 96g, Radix Linderae 96g, Pericarpium Citri Reticulatae Viride (processed with vinegar) 48g, Pericarpium Citri Reticulatae 96g, Fructus Aurantii Immaturus 96g, Fructus Aurantii 96g, stir-frying with ginger juice Cortex Magnoliae Officinalis 96g, vinegar Rhizoma Sparganii 24g processed, vinegar boils Rhizoma Curcumae 24g, Fructus Crataegi 96g, Semen Arecae 120g, Fructus Evodiae (processed) 12g, Cortex Cinnamomi 12g, Radix Et Rhizoma Nardostachyos 15g, Radix Platycodonis 48g, Radix Scutellariae 96g, Radix Et Rhizoma Rhei 48g, Semen Pharbitidis (parched) 48g, and the Radix Aucklandiae, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Fructus Aurantii Immaturus, Fructus Aurantii, Radix Et Rhizoma Nardostachyos are joined to CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 15MPa, 30 ℃ of temperature, CO
2flow 1ml/g crude drug min, extraction time 220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 800W, extracts 2 times, each 10 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 500, every heavy 0.5g.
After testing, in finished product, the content of baicalin is 4.96mg/ sheet.
Embodiment 4: Muxiangliqi Tablet suppresses the experimentation data of mouse mammary tumor cell C127 cell proliferation
1. experiment material
1.1 experiment cell strains
Mouse mammary tumor cell C127 cell, Shandong University's laboratory cell bank, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: Muxiangliqi Tablet of the present invention: press embodiment 1 method preparation.
Medicinal liquid liquid storage: take 100mg Muxiangliqi Tablet, be dissolved in 5ml dehydrated alcohol, 0.2 m filter filters, 500 ldoff pipe subpackages ,-20 ℃ of storages, 0.2 m filter filters dehydrated alcohol in order to the use of matched group simultaneously.
1.3 experiment reagent
DMEM (the Cat.No.12100-061 Lot.No.758137 of GIBCO company); Hyclone (Lot.No.100419 of Tian Hang bio tech ltd, Zhejiang); NaHC0
3(the Cat.No.11810-033 Lot.No. of Shanghai Jiu Yi chemical reagent company limited 1088387); Trypsin(AMRESCO company); EDTA(AMRESCO company); Penicillin G Sodium Salt(AMRESCO company 1); Streptomycin Sulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): the autogamy of PBS(laboratory);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DMIL); Visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX 190); C0
2incubator (FORMA model: 3111); (safe and sound company of Su Jing group manufactures model to super-clean bench: SW-CJ-ZFD); Pure water instrument (U.S. Sprlng company model: S/N 020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai accurate experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 m filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) C127 cell uses DMEM+10%FBS in 37 ℃, 5%C0
2carry out cellar culture (10cm culture dish), when Growth of Cells is during to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml 0.25% trypsin-0.04%EDTA, after 37 ℃ of digestion 2min, add wherein 5ml complete medium neutralization reaction, after piping and druming cell, proceeded in centrifuge tube, the centrifugal 5min of 1000rpm, adjusts concentration of cell suspension 3 * 10
4individual/ml.
2) cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 l, culture plate put into cell culture incubator (37 ℃, 5%C0
2) cellar culture.
3) according to Growth of Cells situation, generally grow to 50%-70%, add Muxiangliqi Tablet solution, continue to cultivate 24h.
4) after 24h, add 20 l MTT solution (5mg/ml, i.e. 0.5%MTT), continue to cultivate 4h.
5) after 4h, buckle method is removed supernatant, with absorbent paper, pats dry gently, and low-speed oscillation 10min on shaking table, as entered 200 l dimethyl sulfoxide, is put in every hole, and crystal is fully dissolved.At enzyme-linked immunosorbent assay instrument 490nm place, measure the light absorption value in each hole.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), sets 6 multiple holes for every group.
7) result represents the suppression ratio of cell with medicine: cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value * 100%.Experiment repeats 3 times.
3. statistical disposition
Adopt correlation analysis and Student t check in Microsoft Excel 2007 softwares, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, with matched group comparison, when dosage reaches 5mg/ml, to C127 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has utmost point significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 1 Muxiangliqi Tablet is on C127 cell inhibitory effect impact research (X ± SD)
| Group | Drug level (mg/ml) | Suppression ratio (%) |
| Matched group | 0 | 0 |
| 1 | 5 | 9.24±8.91 |
| 2 | 10 | 24.6±15.88* |
| 3 | 15 | 34.9±17.92** |
| 4 | 20 | 45.7±18.98** |
Note: with matched group comparison, * P<O.01; * P<0.001.
5. experiment conclusion
Muxiangliqi Tablet can suppress C127 cell proliferation, reduces the Growth of Cells number of C127 cell, and this effect is dose dependent.
Claims (9)
1. the preparation method of a Muxiangliqi Tablet, by Radix Aucklandiae 48g, Rhizoma Cyperi (processed with vinegar) 96g, Radix Linderae 96g, Pericarpium Citri Reticulatae Viride (processed with vinegar) 48g, Pericarpium Citri Reticulatae 96g, Fructus Aurantii Immaturus 96g, Fructus Aurantii 96g, stir-frying with ginger juice Cortex Magnoliae Officinalis 96g, vinegar Rhizoma Sparganii 24g processed, vinegar boil Rhizoma Curcumae 24g, Fructus Crataegi 96g, Semen Arecae 120g, Fructus Evodiae (processed) 12g, Cortex Cinnamomi 12g, Radix Et Rhizoma Nardostachyos 15g, Radix Platycodonis 48g, Radix Scutellariae 96g, Radix Et Rhizoma Rhei 48g, Semen Pharbitidis (parched) 48g make as crude drug, it is characterized in that, described preparation method is comprised of the following step: get the Radix Aucklandiae, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Fructus Aurantii Immaturus, Fructus Aurantii, Radix Et Rhizoma Nardostachyos, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow l-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 1.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extracts 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 500, every heavy 0.5g.
2. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
3. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extracting pressure is 25 MPa.
4. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extraction temperature is 60 ℃.
5. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
6. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extraction time is 200min.
7. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that, described microwave extracting power is 700W.
8. according to the preparation method of the Muxiangliqi Tablet described in claim l, it is characterized in that, the each extraction time of described microwave extracting is 8 minutes.
9. the Muxiangliqi Tablet described in claim l suppresses the application in mouse mammary tumor cell C127 cell proliferation medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310593572.0A CN103638450B (en) | 2013-11-22 | 2013-11-22 | A kind of preparation method of Muxiangliqi Tablet and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310593572.0A CN103638450B (en) | 2013-11-22 | 2013-11-22 | A kind of preparation method of Muxiangliqi Tablet and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103638450A true CN103638450A (en) | 2014-03-19 |
| CN103638450B CN103638450B (en) | 2016-03-09 |
Family
ID=50243822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310593572.0A Expired - Fee Related CN103638450B (en) | 2013-11-22 | 2013-11-22 | A kind of preparation method of Muxiangliqi Tablet and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103638450B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383427A (en) * | 2014-10-21 | 2015-03-04 | 山东永泰化工有限公司 | Preparation method and application of gallstone-dissolving cholagogue tablets |
| CN105521084A (en) * | 2014-11-27 | 2016-04-27 | 武珊珊 | Traditional Chinese medicine for treating abdominal distension |
| CN116159121A (en) * | 2022-12-23 | 2023-05-26 | 贵州威利德制药有限公司 | Preparation method of stomach-nourishing medicine combination with amomum vilosum |
-
2013
- 2013-11-22 CN CN201310593572.0A patent/CN103638450B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383427A (en) * | 2014-10-21 | 2015-03-04 | 山东永泰化工有限公司 | Preparation method and application of gallstone-dissolving cholagogue tablets |
| CN105521084A (en) * | 2014-11-27 | 2016-04-27 | 武珊珊 | Traditional Chinese medicine for treating abdominal distension |
| CN116159121A (en) * | 2022-12-23 | 2023-05-26 | 贵州威利德制药有限公司 | Preparation method of stomach-nourishing medicine combination with amomum vilosum |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103638450B (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690646B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicine for inhibiting mouse lymphoma cell YAC-1 cell proliferation | |
| CN103655843A (en) | Yikangbuyuan tablet, and preparation method and application thereof | |
| CN103638450B (en) | A kind of preparation method of Muxiangliqi Tablet and application | |
| CN103656493A (en) | Preparation method and application of stasis removing and stomach tonifying tablet | |
| CN103690647B (en) | A kind of preparation method of Yikang complement sheet and the application in suppression mouse leukemia cell L6565 cell proliferation thereof | |
| CN103800498A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting mouse prostate cancer cell RM-1 from cell proliferation | |
| CN103655841B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphoid cancer cell P388D1 proliferation | |
| CN103655839B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lung cancer cell LLC proliferation | |
| CN103768267A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell H22 from cell proliferation | |
| CN103800818A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell FO from cell proliferation | |
| CN103655842B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell EL4. IL-2 proliferation | |
| CN103655840B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse leukaemia cell L1210 proliferation | |
| CN103655838B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell L5178Y proliferation | |
| CN103566168B (en) | Preparation method and application of tranquilizing tablets | |
| CN104288658A (en) | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse myeloma cell SP2/0 | |
| CN103751425A (en) | Preparation method of Qingmei cold-treatment tablet and use of Qingmei cold-treatment tablet in drug for inhibiting breast tumor cell C127 proliferation | |
| CN103800770A (en) | Application of boenninghausenia cough tablet in preparing medicine for inhibiting cell proliferation of breast tumor cell C127 | |
| CN103768517A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting mouse lung cancer cell LLC from cell proliferation | |
| CN103784872A (en) | Method for preparing Danshitongli tablets and application of Danshitongli tablets in preparation of medicament for suppressing cell proliferation of ascites tumor cells SAC-IIC3 | |
| CN103768265A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell LLC from cell proliferation | |
| CN103768212A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting stomach cancer cell MFC from cell proliferation | |
| CN103800569A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lymphoma cell YAC-1 from cell proliferation | |
| CN103768207A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell Hepa1-6 from cell proliferation | |
| CN104288659A (en) | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse breast tumor cell C127 | |
| CN104288654A (en) | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse lung cancer cell LLC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Hong Inventor after: Zhang Zaifen Inventor after: Yue Yanqiu Inventor after: Sun Xue Inventor before: Wei Shutong Inventor before: Duan Xuewen |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160111 Address after: Huangdao District Hospital of traditional Chinese medicine, Hainan Island Road, Huangdao District, Qingdao, Shandong 158, China Applicant after: Zhang Hong Address before: 250062, No. ten, No. 16369, Lixia District, Ji'nan City, Shandong Province Applicant before: SHANDONG ZHONGDA PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160309 Termination date: 20171122 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |